We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Low-Cost Near-Patient Diagnostic Platform Rapidly Diagnoses STIs

By LabMedica International staff writers
Posted on 10 Jun 2025

Every day, over one million sexually transmitted infections (STIs) are acquired worldwide. More...

Rapid diagnosis and appropriate antibiotic treatment are crucial to control their spread. Timely testing is necessary to break the transmission chain, enabling patients to receive a diagnosis and begin treatment during the same clinic visit. Although current tests can be used with limited training, they have not yet achieved the target of delivering results within 20 minutes from sample collection. A new, low-cost, near-patient diagnostic platform now promises to detect infections faster than any commercial alternative.

This platform, being developed by Linear Diagnostics (Birmingham, UK), a spin-out from the University of Birmingham, uses Exponential Amplification (EXPAR) technology, which detects bacterial DNA through a rapid signal amplification process. Originally developed and tested during the COVID-19 pandemic at the University, the platform has now demonstrated the ability to detect bacterial STIs, urinary tract infections, and viral infections such as SARS-CoV-2 in as little as five minutes. Recently, the company has focused its efforts on STIs—especially Neisseria gonorrhoeae and Chlamydia trachomatis—given the growing threat posed by multidrug-resistant strains of the former.

Linear is currently refining the cartridge and reader components of the platform and working to validate its performance. By reviewing clinical guidelines and engaging with healthcare providers, patients, and the public, the team aims to understand how best to design and implement the platform to improve patient outcomes. The research will also explore unmet clinical needs, evaluate current diagnostic practices, and determine the most effective stage for introducing this technology in the patient care pathway. Additionally, the researchers will analyze the diagnostic accuracy of the test using data from the innovation lab and assess whether the technology offers cost-effectiveness for the NHS through health economic modelling.

“The most difficult criteria to achieve in diagnostic testing is combining rapidity with accuracy,” said Dr. Jean-Louis Duprey, Head of Research and Development at Linear Diagnostics. “While rapid lateral flow meets the ideal timeframe of 20 minutes to diagnosis, it struggles to meet market requirements for high sensitivity and specificity. And while Nucleic Acid Amplification Tests deliver high accuracy, samples are sent to laboratories for analysis, meaning the waiting time for results may be days. We are developing a near patient device that will overcome this conundrum.”

Related Links:
Linear Diagnostics


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.